ACTRN12620000334909
Withdrawn
N/A
Mechanical suppression of osteolytic bone disease in patients with multiple myeloma using precision exercise medicine: a Phase 1 randomised controlled trial.
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Multiple Myeloma
- Sponsor
- Edith Cowan University
- Enrollment
- 40
- Status
- Withdrawn
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\[1] Multiple myeloma patients with myeloma bone disease (confirmed with clinical imaging). \[2] Required to have not engaged in regular structured exercise in the past three months.
- •\[3] have no current non\-healing skeletal fracture sites,
- •\[4] receive medical clearance to engage in supervised exercise by their haematologist (cancer\-specific contraindications), and general practitioner (for other contraindications).
- •\[5] Is prepared to be randomised to either arm of the study
- •\[6] is not currently receiving an experimental therapy (beyond those in standard of care).
- •Patients with stable and unstable skeletal sites will be included with exercise prescriptions customised based on the location of disease\-affected skeletal sites and the stability status of the disease\-affected skeletal sites. Skeletal stability will be assessed by study clinicians using previously established clinical tools, including Mirel’s scoring system (long bones) and Taneichi’s scoring system (vertebral column). Owing to potential clinical events surrounding spinal osteolytic activity, the spinal instability neoplastic score (SINS) will also be used as a confirmatory tool to support the Taneichi score. In the event of discordance between the two vertebral scoring tools, the higher score will be chosen to remain risk averse. Within a broader multi\-modal exercise program, stable lesion sites will receive a targeted and dose\-escalated exercise stimulus through mechanical loading, whereas unstable lesion sites will be avoided as per our previous work with bone metastases as a similar clinical paradigm for comparison.
Exclusion Criteria
- •\[1] Have a cancer diagnosis other than multiple myeloma.
- •\[2] Does not have Myeloma Bone Disease (clinically confirmed through imaging).
- •\[3] Currently engaging in a regular, structured exercise program pre\-enrolment.
- •\[4] Is not willing to be randomised.
- •\[5] Does not receive medical clearance to participate
- •\[6] Is currently enrolled in an experimental drug trial.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Prevention of bone fracture by intervening in bone quality in type 2 diabetesJPRN-UMIN000002561The Institute for Adult Disease, Asahi Life Foundation300
Completed
Phase 2
Treatment of osteoporosis with unfocused extracorporeal shock wave therapy: pilot studyosteoporosisporous bones10005959NL-OMON41686niversitair Medisch Centrum Utrecht12
Recruiting
N/A
ew Therapies for bone and cartilage defects using bone marrownot applicable1002321310046304NL-OMON43408Orthopaedie200
Not Yet Recruiting
N/A
The effect of osteoporosis drug against bone remodeling around femoral implant after total hip arthroplastyhip osetoarthritis OsteoporosisJPRN-UMIN000020381Mie University Hospital50
Recruiting
N/A
se of Demineralized bone matrix to increase healing capacity in management of Atypical femoral fractureAtypical femoral fractureDemineralized bone matrixDelay unionAtypical femoral fractureDemineralized bone matrixDelay unionTCTR20171028001Faculty of Medicine, Ramathibodi hospital28